Article Information
PubMed
Published By
History
- Received February 26, 2024
- Revision received September 3, 2024
- Accepted September 9, 2024
- Published online September 27, 2024.
Copyright & Usage
Copyright © 2024 Jin and Noble This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- 1Medical Scientist Training Program (MSTP), Columbia University Irving Medical Center (CUIMC), New York, New York 10032
- 2Neurobiology and Behavior (NB&B) Graduate Program, Columbia University, New York, New York 10027
- 3Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University Irving Medical Center, New York, New York 10032
- Correspondence should be addressed to Michelle Jin at mj2947{at}cumc.columbia.edu or James M. Noble at jn2054{at}columbia.edu.
Author contributions
Author contributions: M.J. and J.M.N. wrote the paper.
Disclosures
The authors declare no competing financial interests.
We thank Dr. Christine Ann Denny for her constructive feedback on an initial draft of this manuscript. This work was supported by the National Institute of General Medical Sciences (T32GM007367 to M.J./Columbia MSTP) and by the National Institute on Aging (F30AG084312 to M.J.).
Funding
HHS | NIH | National Institute of General Medical Sciences (NIGMS)
T32GM007367HHS | NIH | National Institute on Aging (NIA)
F30AG084312
Article usage
In this issue
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease
